You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Oct 27, 2026; less than a full year is stored.
Sun Pharma reported Q2 FY27 sales of Rs. 161,000,000, up 11.8%, and EBITDA of Rs. 47,439 million, up 4.8%. The Organon acquisition remains on track to close by early 2027, while India formulations sales rose 17.3% to Rs. 55,523 million.
Illustrative technical + ownership context — a signal mix, not investment advice.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XBOM:SUNPHARMA | +3.4% | — | — | +6.1% | — |
Share classes and depositary receipts can have different prices and dividends.
| Ex-dividend date | Amount per share |
|---|---|
| 2026-07-07 | 5.00 INR |
| 2026-02-05 | 11.00 INR |
| 2025-07-07 | 5.50 INR |
| 2025-02-06 | 10.50 INR |
| 2024-07-12 | 5.00 INR |
| 2024-02-09 | 8.50 INR |
| 2023-07-28 | 4.00 INR |
| 2023-02-08 | 7.50 INR |
| 2022-08-19 | 3.00 INR |
| 2022-02-09 | 7.00 INR |
| 2021-08-23 | 2.00 INR |
| 2021-02-09 | 5.50 INR |
| 2020-08-19 | 1.00 INR |
| 2020-02-17 | 3.00 INR |
| 2019-08-20 | 2.75 INR |
| 2018-09-17 | 2.00 INR |
| 2017-09-18 | 3.50 INR |
| 2016-09-08 | 1.00 INR |
| 2015-10-21 | 3.00 INR |
| 2014-09-11 | 1.50 INR |
No upcoming investor events are listed for this company yet.
